NCT01452061View on ClinicalTrials.gov

Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder

CompletedOBSERVATIONAL
Enrollment

456

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Autism Spectrum DisorderAttention Deficit/Hyperactivity DisorderDevelopmental Delay
Trial Locations (1)

44104

Cleveland Clinic Center for Autism, Cleveland

Sponsors

Collaborators (1)

IntegraGen SA
All Listed Sponsors
collaborator

IntegraGen SA

INDUSTRY

lead

Thomas W. Frazier, Ph.D

OTHER

NCT01452061 - Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter